```text
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, represents a valuable research substance extensively employed in cardiovascular research . This Fab fragment primarily targets the glycoprotein IIb/IIIa binding site on platelets , blocking platelet aggregation . As a result, it's commonly employed as a tool to examine the processes underlying thrombosis and to assess the efficacy of anticoagulant therapies. Supply is typically controlled to institutional settings.
```
Abciximab Research: Utilizing C7E3 and Compound 143653-53-6 in Studies
Ongoing studies into abciximab, a platelet aggregation inhibitor, frequently incorporates the monoclonal antigen C7E3 and the molecule identified as 143653-53-6. These materials are essential for examining abciximab's biological activity, assessing its efficacy in different patient populations, and exploring potential indicators of treatment response. Additional investigation leveraging these precise reagents is likely to generate valuable data for enhancing clinical applications concerning cardiovascular conditions.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab Abciximab antibody facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Analyzing Scientific Avenues with the Drug Abciximab 143653-53-6 and C7E3
Recent research demonstrate that Abciximab (identified as 143653-53-6) holds significant investigative promise, particularly when associated with C7E3. Early observations indicated that this association may improve therapeutic responses in various heart-related settings. Further investigation is centered on elucidating the precise process of action between this inhibitor and C7E3, involving study of platelet clumping and arterial preservation.
- Ongoing study efforts aim to maximize administration approaches.
- Laboratory models are are being applied to further confirm these theories.
- Clinical studies will be necessary to thoroughly evaluate patient benefit.
```
Abciximab (C7E3) for Research: Quality and Details (143653-53-6)
Researchers requiring abciximab for experimental investigations should rigorously evaluate purity and precise parameters . This product is typically provided as a solid powder and comprehensive analytical documentation including assessment by LC-MS, potency assays, and endotoxin testing must be available. Verify the supplier's documentation specifies acceptable ranges for impurities and fulfills established QC criteria .
Research-Grade C7E3 Details & Stock
Acquiring research-grade Abciximab, specifically referencing the compound C7E3 and identified by the chemical number 143653-53-6, requires thorough consideration of its origin . This agent is frequently utilized in in vitro studies , particularly those focused on platelet aggregation and clotting . Existing sources offer this substance in varying quantities , typically ranging from g to larger wholesale supplies. We suggest reviewing the certificate of analysis to verify purity and applicability for your specific use . Moreover, check the stability date before purchasing to maintain ideal effectiveness.
- Typical Purity: >95%
- Storage Conditions: -20°C and suitable conditions
- Intended Purpose: Platelet Clumping Inhibition Studies